Glioblastoma has long stood as one of the most discouraging frontiers in cancer immunotherapy. Despite the remarkable success of immune checkpoint blockade in melanoma, lung cancer, and a growing list of other malignancies, the most aggressive primary brain tumor in adults has remained largely impervious to drugs that unleash T cells elsewhere in the body. Now, a team of researchers at the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing reports that an unexpected candidate—a synthetic antibiotic called clofoctol, developed decades ago and never before central to cancer immunology—may help crack that resistance. In a study published in Cancer Immunology, Immunotherapy, the investigators show that clofoctol reshapes the distribution and function of CD8-positive T cells throughout the body and, when paired with an anti-PD-1 antibody, produces markedly better tumor control and longer survival in a mouse model of glioblastoma than either treatment alone.
The rationale behind the study rests on a strategy that has gained considerable traction in oncology: drug repurposing. Bringing a brand-new molecule from discovery to the clinic can take well over a decade and cost more than a billion dollars, whereas established drugs come with known safety profiles, manufacturing routes, and, in some cases, prior human exposure data. Clofoctol, an antibiotic with a long clinical history in parts of Europe, had already attracted attention for direct antitumor activity in preclinical studies. What remained poorly understood—and what motivated the Beijing team led by Yue Wang, Wei Han, and Xiaozhong Peng—was whether the drug could also act on the immune landscape of glioblastoma, a tumor whose microenvironment is famously hostile to infiltrating lymphocytes.
To probe that question, the researchers turned to an orthotopic GL261 model, in which glioblastoma cells are implanted directly into the brains of immunocompetent mice. This model is widely regarded as one of the most faithful experimental systems for glioblastoma immunology because it preserves an intact blood-brain barrier and an intact immune system, both of which are essential when the question at hand concerns systemic immune trafficking. Using flow cytometry, the team compared the immune composition of tumors from clofoctol-treated animals against controls, and the differences were striking. Tumors from treated mice contained a substantially higher proportion of CD8-positive cytotoxic T cells—the immune system’s primary tumor-killing operatives—and those cells expressed elevated levels of cytotoxic effector molecules, hallmarks of a tumor microenvironment shifting from immunologically cold to immunologically active.
Perhaps the most intriguing finding, however, lay outside the tumor itself. When the researchers analyzed the composition of cells in the bone marrow, they observed that glioblastoma was associated with an accumulation of T cells sequestered in that compartment, a phenomenon consistent with the systemic T-cell dysfunction that increasingly is recognized as a barrier to immunotherapy in brain tumors. Clofoctol treatment partially relieved this sequestration, promoting a redistribution of T cells back into systemic circulation and, ultimately, into the tumor. In other words, the drug appears to work not only within the tumor microenvironment but at the level of whole-body immune architecture, releasing a reservoir of cytotoxic lymphocytes that the tumor had effectively locked away.
The causal importance of CD8-positive T cells to the therapeutic effect was confirmed in a depletion experiment. When the researchers eliminated CD8-positive T cells from the animals, the antitumor efficacy of clofoctol was markedly attenuated. That result matters because it elevates the drug from a possible bystander to a demonstrably T-cell-dependent intervention: whatever else clofoctol may be doing to tumor cells directly, its benefit in this model hinges on the presence of a functional cytotoxic T-cell population. For a field in which many repurposed drugs show antitumor effects that turn out to be independent of immunity—and therefore unlikely to synergize with checkpoint blockade—this distinction is critical.
In vitro co-culture experiments added a second layer of mechanistic support. When CD8-positive T cells were pretreated with clofoctol and then exposed to target cells, their cytotoxic activity increased, accompanied by upregulated expression of granzyme B, perforin, and interferon-gamma—the molecular arsenal that cytotoxic lymphocytes use to punch holes in target-cell membranes and trigger programmed cell death, along with the inflammatory cytokine that amplifies antitumor immune signaling. The drug, in short, did not merely deliver more T cells to the tumor; it made the T cells that arrived more lethal.
To trace the signaling pathway behind this activation, the team employed an affinity-based chemoproteomic approach known as ITSA-MS, which screens for proteins that bind a drug of interest in cellular lysates. That screen identified BCL9, a scaffolding protein best known for its role in Wnt signaling and previously implicated in various cancers, as a candidate clofoctol-responsive protein. Subsequent western blot analyses revealed that clofoctol treatment was associated with increased phosphorylation of VAV1, AKT, and ERK—a cascade of signaling events well established in T-cell activation, in which VAV1 relays receptor proximal signals downstream to AKT and ERK pathways that drive proliferation, survival, and effector differentiation. The authors are careful to note that the precise regulatory relationship between BCL9 and this phosphorylation cascade remains to be worked out, but the convergence of chemoproteomic and biochemical evidence points to a coherent mechanism by which the antibiotic potentiates T-cell function.
The translational payoff came in the combination experiments. Glioblastoma’s failure to respond to PD-1 blockade is thought to stem from multiple converging deficits: a physically and immunologically protected location behind the blood-brain barrier, a profoundly immunosuppressive microenvironment, and a systemic T-cell compartment that is itself dysfunctional. Checkpoint inhibitors address only one link in that chain—releasing the molecular brakes on T cells—but they cannot help if there are too few functional T cells reaching the tumor in the first place. Clofoctol, according to the new data, addresses complementary links in the chain by mobilizing T cells from the bone marrow and sharpening their cytotoxic program. When the researchers combined clofoctol with an anti-PD-1 antibody, the treated animals showed greater intratumoral CD8-positive T cell abundance and effector activity, tighter tumor control, and significantly prolonged survival compared with either monotherapy.
The implications extend beyond glioblastoma itself. The finding that a systemically administered, clinically familiar small molecule can redistribute T cells from a bone marrow reservoir and enhance their killing capacity suggests a generalizable strategy for tumors characterized by T-cell sequestration and exhaustion. It also adds to a growing appreciation that the bone marrow acts as a dynamic immunological compartment in cancer, one that can be therapeutically targeted rather than simply observed. If the mechanisms hold up in further studies, clofoctol-like approaches could complement checkpoint blockade in other poorly immunotherapy-responsive cancers, where the limiting factor is not T-cell priming but T-cell delivery and function.
Considerable caution is nonetheless warranted before extrapolating to patients. The findings derive from a single murine model, and glioblastoma models have a well-documented history of promising immunotherapy results that failed to translate into human benefit. The authors themselves emphasize that the link between BCL9 and the observed signaling changes requires further investigation, and the dosing, safety, and pharmacokinetic questions specific to combining an antibiotic with checkpoint inhibitors in the setting of brain tumors remain open. Still, the study exemplifies the promise of drug repurposing viewed through an immunological lens: an old molecule, examined with modern flow cytometry, chemoproteomics, and combination-design thinking, reveals an unexpected capacity to reorganize the immune system in ways that make immunotherapy work better. For a disease whose median survival has barely moved in decades, that is a direction worth pursuing with urgency.
Subject of Research: Repurposing the antibiotic clofoctol to enhance T-cell-mediated immunotherapy response in glioblastoma
Article Title: Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma
Article References: Clofoctol promotes systemic T-cell redistribution and intratumoral cytotoxicity to improve the response to PD-1 blockade in glioblastoma. (n.d.). https://doi.org/10.1007/s00262-026-04544-3
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04544-3
Keywords: glioblastoma, clofoctol, drug repurposing, immunotherapy, PD-1 blockade, CD8-positive T cells, bone marrow, tumor microenvironment, BCL9, granzyme B, immune checkpoint blockade, Cancer Immunology Immunotherapy
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (October 3, 2026). Old Antibiotic Clofoctol Rewires the Immune System to Boost Glioblastoma Immunotherapy. Scienmag. https://scienmag.com/old-antibiotic-clofoctol-rewires-the-immune-system-to-boost-glioblastoma-immunotherapy/
Nathaniel Bowman. “Old Antibiotic Clofoctol Rewires the Immune System to Boost Glioblastoma Immunotherapy.” Scienmag, 3 October 2026, https://scienmag.com/old-antibiotic-clofoctol-rewires-the-immune-system-to-boost-glioblastoma-immunotherapy/. Accessed 3 October 2026.
Nathaniel Bowman. “Old Antibiotic Clofoctol Rewires the Immune System to Boost Glioblastoma Immunotherapy.” Scienmag. October 3, 2026. https://scienmag.com/old-antibiotic-clofoctol-rewires-the-immune-system-to-boost-glioblastoma-immunotherapy/
Copy citation Download RIS
Tags: anti-PD-1 antibody synergyBCL9bone marrowboosting glioblastoma immunotherapybrain tumor immune resistanceCancer Immunology ImmunotherapyCD8-positive T cell redistributionCD8-positive T cellsclofoctolclofoctol as immune modulatordrug repurposingdrug repurposing in cancer treatmentGlioblastomaglioblastoma immunotherapygranzyme Bimmune checkpoint blockadeimmune checkpoint blockade resistanceimmune system rewiring for cancerImmunotherapynovel cancer immunotherapy strategiesPD-1 blockaderepurposed antibiotics in cancertumor control and survival in glioblastomatumor microenvironment
